Dr Benjamin Koh obtained his medical degree from the National University of Singapore and a Master of Public Health from Harvard University. He has had previous experience handling communicable disease control, international health relations and health service development in Ministry of Health (MOH).
He has also worked on enterprise and entrepreneurship development in the Ministry of Trade and Industry, and was the Senior Director in charge of service delivery and development in the Ministry of Social and Family Development. He was the Coordinating Divisional Director for Higher Education in the Ministry of Education, overseeing policies on higher education and academic research.
Dr Koh is the Deputy Secretary (Development) in MOH. He oversees issues relating to infrastructure and manpower development for the healthcare sector in Singapore, as well as matters relating to ageing and eldercare.
Mr Beh Kian Teik
Mr Beh Kian Teik is the Chief Executive Officer of the National Research Foundation (NRF). He is responsible for planning, reviewing, developing and implementing the national Research, Innovation and Enterprise (RIE) strategies and governance frameworks, to grow and sustain a vibrant RIE ecosystem in Singapore. He plays an instrumental role in obtaining national consensus on research priorities, to guide long-term strategic Research & Development (R&D) investment decisions by the NRF Board.
Kian Teik is concurrently the Executive Vice President of the Singapore Economic Development Board (EDB). He oversees EDB New Ventures. He works with corporate entrepreneurs with the passion and drive to create early stage ventures in Singapore. He has over twenty years’ experience of promoting Foreign Direct Investment (FDI) and building industries in the manufacturing and internationally tradeable services sectors.
Previously, he was responsible for EDB’s activities in innovation & industry incubation and led effort to foster industry-science linkages. In 2010, he was also the founding director of the Singapore Biomedical Sciences Industry Partnership Office, a unique inter-agency government organisation. In this role, he worked with senior Singapore scientists to partner industry to translate science to medicine, and with industry partners that desire to undertake R&D projects requiring the capabilities of multiple Singapore agencies, in basic sciences and clinical research.
Kian Teik joined EDB in February 1998 and has held roles of increasing responsibilities in EDB. His previous leadership roles included developing the biomedical sciences cluster, attracting European FDI from Europe and running the IT, planning, research and statistics operations. He is a Sundstrand-EDB and Glaxo-EDB scholar who graduated from the University of California, Berkeley with an MSc in Electrical Engineering, as well as a BSc in Electrical & Computer Engineering from the University of Illinois at Urbana-Champaign.
Prof Chong Yap Seng
Professor Chong Yap Seng is the Chief Clinical Officer of SICS and the Founding Director of the A*STAR-NUS Singapore Centre for Nutritional Sciences, Metabolic Disease, and Human Development. He is also a Senior Consultant in the Department of Obstetrics & Gynaecology with the National University Health System (NUHS), and the Dean of the Yong Loo Lin School of Medicine in the National University of Singapore.
A clinician-scientist with special interest in foetal growth and early development, Professor Chong is the Lead Principal Investigator for Growing Up in Singapore Towards healthy Outcomes (GUSTO) – a nationwide birth cohort study on pregnancies and early childhood development. Key discoveries on gestational diabetes and its impact on children has made systemic changes towards Singapore’s public health policy in a matter of months. Professor Chong was awarded the National Outstanding Clinician Scientist Award by the Ministry of Health in 2017.
Professor Chong received his MBBS, MMed (Obstetrics & Gynaecology) and MD from the National University of Singapore.
Prof Barry Halliwell
Professor Barry Halliwell is Senior Advisor, Academic Appointments and Research Excellence, Office of the Senior Deputy President and Provost.
Professor Halliwell graduated from the University of Oxford with BA (1st class) and D.Phil degrees. He holds a D.Sc degree from the University of London. He was a faculty member with the University of London, King’s College from 1974 to 2000 and held a prestigious Lister Institute Research fellowship. From 1995 to 1999, he was a Visiting Research Professor of Internal Medicine and Biochemistry with the University of California Davis, School of Medicine, Divisions of Cardiology and Pulmonary/Critical Care Medicine. Professor Halliwell was a Visiting Professor of Biochemistry to NUS from 1998 to 2000. He was Head of the University’s Department of Biochemistry from 2000 to 2007 and was Deputy Director, Office of Life Sciences from 2001 to 2003. From 2003 to September 2008, he was the founding Executive Director of the newly-formed NUS Graduate School of Integrative Sciences and Engineering. From Mar 2006 to May 2015, he was the Deputy President (Research and Technology) at NUS. From Jun 2015 to May 2018, he was the Senior Advisor to the President at the National University of Singapore.
An internationally-acclaimed biochemist, Professor Halliwell is known especially for his seminal work on the role of free radicals and antioxidants in biological systems. The Thomson Reuters lists Professor Halliwell as one of the world’s most highly-cited researchers in Biology and Biochemistry and his Hirsch Index is 164. (Based on Scopus, Jun 2021).
His book Free Radicals in Biology and Medicine published by Oxford University Press, and now in its fifth edition, is regarded worldwide as an authoritative text in the field. He has received numerous research awards, including Singapore President’s Science and Technology Medal (2013), the “Lifetime Achievement Award” by the Society for Free Radical Biology and Medicine in the USA for overall sustained excellence in the field and the Ken Bowman Research Award for outstanding achievements in the field of cardiovascular research from the Institute of Cardiovascular Sciences (Canada).
His research focuses on the role of free radicals and antioxidants in human disease, particularly Alzheimer’s disease and other brain disorders. His interest in identifying the most important antioxidants in the human diet and in developing novel antioxidants has critical bearing on treating human diseases and understanding how diet might cause or prevent them.
Professor Halliwell is a member of several editorial boards including FEBS Letters, Biochemical and Biophysical Research Communications and Antioxidants and Redox Signaling. He has been a lead speaker at Gordon Conferences and other prestigious events worldwide and is a member of several expert advisory panels to leading universities, companies and government agencies.
Dr Vincent Ho
Dr Vincent Ho is Director at the National Research Foundation (NRF), Singapore. He leads the Human Health and Potential (HHP) Directorate in developing and driving research, innovation and enterprise strategies of Singapore’s HHP domain.
Prior to joining NRF, Dr Ho was an independent Research Fellow in the Molecular Engineering Laboratory founded by the late Nobel Laureate Dr Sydney Brenner. He was a recipient of a National Science Scholarship awarded by the Agency for Science, Technology and Research (A*STAR), Singapore.
Dr Ho received his Ph.D. from the University of Cambridge, and B.Sc. in Chemical Engineering (Magna cum Laude) from the University of Illinois at Urbana-Champaign.
Prof William Hwang
Professor William Hwang is the Medical Director of the National Cancer Centre of Singapore (NCCS), Chair of the Oncology Academic Clinical Programme (ACP) in the SingHealth Duke-NUS Academic Medical Centre, Head of the SingHealth Duke-NUS Cell Therapy Centre, and one of the research faculty in the Duke-NUS Cancer and Stem Cell Biology (CSCB) programme. He is serving as Chairman, Biobanking Advisory, Ministry of Health (MOH); Co-Chair, National Advisory Committee on Cancer Care (NACC), MOH; Co-Chair, Cell, Tissue and Gene Therapy (CTGT) Regulations workgroup, MOH; Member, Hematopoietic Stem Cell Transplant Regulations workgroup, MOH. He is also Board Organising Committee (BOC) member of the Singapore Translational Cancer Consortium.
He has previously served as Medical Director of the Singapore Cord Blood Bank, Head for the Department of Haematology in the Singapore General Hospital and Head of the SingHealth Duke-NUS Blood Cancer Centre as well as Director for SingHealth Transplant.
He was previously President of the World Marrow Donor Association (WMDA), and Advisory Board member of the Centre for International Blood and Marrow Transplant Research (CIBMTR, based in the USA). He served as Congress President for the 2016 Asia Pacific Blood and Marrow Transplant Group (APBMT) meeting and currently serves as Executive Board member of the APBMT.
Prof Hwang has published over 120 papers in medicine and science, particularly in the field of haematology and HSC.
Prof Ng Huck Hui
Professor Ng Huck Hui is the Assistant Chief Executive of the Biomedical Research Council, under the Agency for Science, Technology and Research.
Prof Ng is renowned in the field of gene regulation and genomics. His laboratory is developing diagnostic and therapeutics modalities for brain and liver diseases. Prof Ng had held several administrative positions. He was the Executive Director of the Genome Institute of Singapore and the Executive Director of the A*STAR Graduate Academy.
Prior to joining A*STAR, Prof Ng was a postdoctoral fellow with Harvard Medical School under the prestigious Damon Runyon-Walter Winchell Postdoctoral Fellowship. Prof Ng is renowned in the field of stem cells, having spent more than a decade in research to understand and uncover the intricacies of gene regulation and how they relate to cell biology. He was also the President for the Stem Cell Society Singapore, which is a major platform for educating the public on stem cell research. In 2016, Prof Ng was elected to be an Associate Member of the European Molecular Biology Organization, making him the only associate member to be based in Singapore. Most recently, Prof Ng was also elected as Fellow of the Singapore Academy of Science (SNAS).
In recognition of his scientific contributions, Prof Ng has received numerous local and international honours and awards, including the Young Scientist Award in 2004, Singapore Youth Award in 2005, National Science Award in 2007, Junior Chamber International (JCI) The Outstanding Young Persons Singapore Awards in 2009, Singapore Youth Award (Commendation Medal) in 2010, President’s Science Award (Team Award) in 2011, President’s Science Award (Team Award) in 2018 and The Public Administration Medal (Silver), National Day Awards 2019.
Outside of A*STAR, Prof Ng is very active in the local universities and organizations, and holds adjunct positions at the National University of Singapore (NUS) Yong Loo Lin School of Medicine, NUS Faculty of Science, Nanyang Technological University (NTU) School of Biological Sciences and LKC Medicine and the Singapore Eye Research Institute (SERI). He also sits on the Board of Consortium for Clinical Research and Innovation Singapore (CRIS) Pte Ltd, National Medical Research Council (NMRC), Science Centre Singapore and NUS High School.
Ms. Elaine Teo
BSc. Pharmacy (Hons.), MSc. (Pharmacy), M. (Public Management)
Ms Elaine Teo is the Director, Aged and Ancillary Services Regulation, and Regulatory Transformation in the Health Regulation Group, Ministry of Health, Singapore.
Trained as a pharmacist, Ms Teo has been with the Singapore Ministry of Health (MOH) since 2003 where she was instrumental in the establishment of the Optometrists and Opticians Board, the Allied Health Professions Council (AHPC), and the Agency for Care Effectiveness (ACE). At AHPC, she served as the inaugural registrar where she led the successful state licensure and professional regulation for key allied health professions. As Head of the policy and planning team in ACE, she facilitated international collaborations for capacity building, and orchestrated the launch of ACE’s first guidances to positive reception, securing sustained cooperation and resources for ACE’s new initiatives and subsequent expansion.
Currently, as a director in the Health Regulation Group, she oversees the regulation of the aged care and ancillary services sectors to assure patient safety; and champions regulatory transformation through regulatory sandboxes, use of analytics, consumer engagement and education initiatives for more agile regulatory responses to new risks emerging in the rapidly evolving healthcare landscape.
Prof Ashok Venkitaraman
Professor Ashok Venkitaraman is the Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at NUS Yong Loo Lin School of Medicine, a member of the National University Health System (NUHS). He holds a joint appointment at the Agency for Science, Technology and Research (A*STAR).
Prof Venkitaraman’s research has contributed fundamentally to our understanding of how cancer is suppressed by genes that maintain the integrity of DNA in the human genome. His laboratory is recognized for the discovery that mutations in the breast and ovarian cancer gene, BRCA2, provoke genome instability leading to carcinogenesis. Prof Venkitaraman now seeks to achieve a deeper understanding of the steps that underlie carcinogenesis, in order to find new strategies to intercept cancer development well before the disease reaches an advanced and hard-to- treat stage. He has developed new technologies to target previously ‘undruggable’ targets, and is a serial biotech entrepreneur, most recently as a founder of PhoreMost Ltd.
Prof. Venkitaraman has been elected a Fellow of the Academy of Medical Sciences, London, and as a member of EMBO.
Prof Chng Wee Joo
Executive Director, Singapore Translational Cancer Consortium;
Deputy Director & Senior Principal Investigator, Cancer Science Institute of Singapore, NUS;
Provost’s Chair & Professor, Yong Loo Lin School of Medicine, National University of Singapore;
Director, National University Cancer Institute, Singapore (NCIS);
Head and Senior Consultant, Division of Haematology, Department of Haematology-Oncology, NCIS;
Leader, Haematologic Malignancy Tumour Group, NCIS
Profess Chng Wee Joo is the Executive Director of the Singapore Translational Cancer Consortium. He obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. He completed his Fellowship training in haematology in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics.
He is a member of many international professional committees, such as American Society of Haematology Scientific Committee on Plasma Cell Neoplasia, the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 200 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his research both locally and internationally including the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.
Professor Chng’s current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.
Prof Lim Soon Thye
Co-Director, Singapore Translational Cancer Consortium; Deputy Group Chief Executive Officer (Research & Education) Singapore Health Services;
Deputy Medical Director (Clinical), National Cancer Centre Singapore;
Senior Associate Dean, MD Programme, Duke-NUS Medical School
Professor Lim Soon Thyegraduated from the National University of Singapore and subsequently obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California. Currently, he is a senior consultant and deputy medical director (clinical) at NCCS. He also heads Singhealth-DukeNUS Blood Cancer Centre and a regular rank professor at Duke-NUS medical school.
His other leadership roles and positions include serving as the chairman of the Singhealth Central Institutional Review Board-B, director of ACP Oncology Clinical Service, chairman of the cancer service line development and chairman of the national medical oncology residency advisory committee. Additionally, he is also the current associate Dean for Clinical Education at Duke-NUS medical school. Prof Lim previously served as the president of the Singapore Society of Oncology from 2006 to 2010, and chairman of the chapter of Medical Oncologist, Academy of Medicine Singapore from 2010 to 2014. He is an active council member at the Singapore Cancer Society (SCS) where he also chairs the SCS medical professional and audit committee as well as the cancer treatment fund committee.
Prof Lim’s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He has published more than 100 papers in high impact international journals such as Cancer Cell, Lancet Oncology and Journal of Clinical Oncology. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centres across Asia.
Prof Lim was also the Principal Lead Investigator of a Translational and Clinical Research (TCR) Flagship Programme, Large Collaborative Grant (LCG) funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics from 2014 to 2019; Singapore lYMPHhoma TranslatiONal studY from 2019-2024).
Additionally, his team leads the blood cancer (T cell lymphoma) genomics project at the International Cancer Genomics Consortium. His group has been successful in securing more than S$20 million of NMRC, industrial and philanthropic funding over the years. His research efforts won him the 3rd Kobayashi Foundation Award in May 2014 in Taipei. This award was created to recognize distinguished research achievements in the field of cancer in Asian countries. Previously, he was also awarded Singhealth Distinguished Young leader Award in 2011. In 2015, he is also conferred the title of Tanoto Professorship in Medical Oncology. More recently, he is also part of an international team that won the American Association of Cancer Research (AACR) Team Science Award. The AACR Team Award is a prestigious award that recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that advances our fundamental knowledge of cancer.
Prof Goh Boon Cher
Platform Lead, Cancer Clinical Trials and IMUs, Singapore Translational Cancer Consortium;
Deputy Director, Cancer Science Institute of Singapore;
Deputy Director, National University Cancer Institute, Singapore (Research);
Senior Consultant, Department of Hematology-Oncology, National University Cancer Institute, Singapore;
Professor, Department of Pharmacology & Department of Medicine, National University of Singapore;
Group Chief, Physician Leadership and Organisation Development Office, National University Health System, Singapore
Professor Goh Boon Cher received his undergraduate medical education at the National University of Singapore, and joined the Department of Hematology-Oncology, NUH where he completed fellowship in medical oncology, and completed a National Medical Research Council fellowship in clinical pharmacology and phase I clinical trials at the University of Chicago. Professor Goh has established himself as a leading clinician scientist in clinical pharmacology and cancer drug development, and currently serves on several institutional and national research portfolios. He has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. As a clinician, Professor Goh is well established in the fields of head and neck/lung cancer. As a senior clinician and scientist, he has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in being awarded research grants as principal investigator of both individual project grants and infrastructure grants. Beyond cancer therapeutics, he is also widely published in pharmacogenetics, studying how human genetics affect drug response. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel drugs, and has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology. As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board.